epidermodysplasia verruciformis: an unusual malignant transformation
Clicks: 182
ID: 248672
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
182 views
24 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #77 of 318 articles by views in crystallization of organic compounds: an industrial perspective
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Epidermodysplasia verruciformis (EV) is a rare, life-long heritable disease caused due to a unique susceptibility to human papilloma virus. The disseminated verrucous lesions and pityriasis versicolor-like lesions persist from early childhood and can transform into a cutaneous malignancy in a fourth of patients. Malignant transformation into syringoid eccrine carcinoma (SEC) has been reported only once so far. SEC is an extremely invasive, rare, locally destructive, slowly growing adnexal tumor. We hereby report the association of EV with SEC in a 29-year-old male.
| Reference Key |
agrawal2013indianepidermodysplasia
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Prachi G Agrawal;Sunanda A Mahajan;Uday S Khopkar;Vidya D Kharkar |
| Journal | crystallization of organic compounds: an industrial perspective |
| Year | 2013 |
| DOI |
10.4103/0378-6323.104677
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.